Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List
Insmed (Nasdaq:INSM) has secured the #1 position in Science's 2024 Top Employers Survey for the fourth consecutive year. The survey, which gathered nearly 6,500 responses primarily from North America (65%), Europe (19%), and Asia/Pacific Rim (11%), evaluates companies in biotechnology and pharmaceutical industries.
The company stood out for its innovative leadership, respect for employees, social responsibility, and employee loyalty. With over 1,200 employees worldwide, Insmed has demonstrated strength in commercial and pipeline programs while maintaining its commitment to transforming patients' lives with serious diseases. The recognition highlights Insmed's distinctive culture and continued global expansion.
Insmed (Nasdaq:INSM) ha conquistato la posizione #1 nel Survey dei Migliori Datori di Lavoro 2024 di Science per il quarto anno consecutivo. L'indagine, che ha raccolto quasi 6.500 risposte principalmente da Nord America (65%), Europa (19%) e Asia/Pacifico (11%), valuta le aziende nei settori biotecnologico e farmaceutico.
L'azienda si è distinta per la sua leadership innovativa, il rispetto per i dipendenti, la responsabilità sociale e la lealtà dei dipendenti. Con oltre 1.200 dipendenti in tutto il mondo, Insmed ha dimostrato forza nei programmi commerciali e di pipeline mantenendo il suo impegno a trasformare la vita dei pazienti affetti da malattie gravi. Questo riconoscimento mette in luce la cultura distintiva di Insmed e la sua continua espansione globale.
Insmed (Nasdaq:INSM) ha logrado la posición #1 en la Encuesta de los Mejores Empleadores de Science 2024 por cuarto año consecutivo. La encuesta, que recopiló casi 6,500 respuestas, principalmente de América del Norte (65%), Europa (19%) y Asia/Pacífico (11%), evalúa empresas en las industrias biotecnológica y farmacéutica.
La compañía destacó por su liderazgo innovador, respeto hacia los empleados, responsabilidad social y lealtad del personal. Con más de 1,200 empleados en todo el mundo, Insmed ha demostrado fortaleza en sus programas comerciales y de pipeline, mientras se mantiene comprometida a transformar la vida de los pacientes con enfermedades graves. Este reconocimiento resalta la cultura distintiva de Insmed y su continua expansión global.
Insmed (Nasdaq:INSM)는 Science의 2024년 최고의 고용주 설문조사에서 4년 연속 1위를 차지했습니다. 이 설문조사는 주로 북미(65%), 유럽(19%), 아시아/태평양(11%)에서 약 6,500개의 응답을 수집하여 생명공학 및 제약 산업의 기업을 평가합니다.
회사는 혁신적인 리더십, 직원에 대한 존중, 사회적 책임 및 직원 충성도로 두드러졌습니다. Insmed는 전 세계에 1,200명 이상의 직원을 두고 있으며 심각한 질병을 앓고 있는 환자의 삶을 변화시키겠다는 헌신을 유지하면서 상업 및 파이프라인 프로그램에서 강한 실적을 보여주었습니다. 이 인식은 Insmed의 독특한 문화와 지속적인 글로벌 확장을 강조합니다.
Insmed (Nasdaq:INSM) a obtenu la première place dans le Grand Prix des Meilleurs Employeurs 2024 de Science pour la quatrième année consécutive. L'enquête, qui a recueilli près de 6 500 réponses principalement d'Amérique du Nord (65 %), d'Europe (19 %) et de la région Asie/Pacifique (11 %), évalue les entreprises dans les industries biotechnologique et pharmaceutique.
La société s'est démarquée par son leadership innovant, son respect des employés, sa responsabilité sociale et la fidélité de ses employés. Avec plus de 1 200 employés dans le monde, Insmed a démontré sa force dans les programmes commerciaux et de pipeline tout en maintenant son engagement à transformer la vie des patients atteints de maladies graves. Cette reconnaissance met en lumière la culture distinctive d'Insmed et son expansion mondiale continue.
Insmed (Nasdaq:INSM) hat im Science's 2024 Top Employers Survey zum vierten Mal in Folge den ersten Platz gesichert. Die Umfrage, die nahezu 6.500 Antworten überwiegend aus Nordamerika (65%), Europa (19%) und Asien/Pazifik (11%) sammelte, bewertet Unternehmen in der Biotechnologie- und Pharmaindustrie.
Das Unternehmen zeichnete sich durch seine innovative Führung, den Respekt vor den Mitarbeitern, soziale Verantwortung und Mitarbeiterloyalität aus. Mit über 1.200 Mitarbeitern weltweit hat Insmed Stärke in den kommerziellen Programmen und Pipeline-Initiativen bewiesen und dabei sein Engagement für die Veränderung des Lebens von Patienten mit schweren Krankheitsbildern aufrechterhalten. Die Anerkennung unterstreicht die unverwechselbare Kultur von Insmed und die kontinuierliche globale Expansion.
- None.
- None.
—Insmed Leads Science Top Employers List for Fourth Year in a Row—
"It is a tremendous honor to have been named the No. 1 employer in Science's annual survey for the fourth consecutive year," said Will Lewis, Chair and Chief Executive Officer of Insmed. "This past year has been transformational for our company, as we've demonstrated the strength of our commercial and pipeline programs, continued to fuel the innovation engine behind our early-stage research, and enhanced our culture while growing to more than 1,200 employees around the world. Looking to the future, I am filled with pride and excitement as I think about the talent, dedication, and potential of our team as we strive to make a real difference in the lives of patients with serious diseases."
The 2024 survey results were based on nearly 6,500 responses from individuals located primarily across
"The culture we've built at Insmed is unlike any other I've experienced, and I am proud to see it continue to grow and strengthen as we expand our global team," said Nicole Schaeffer, Chief People Strategy Officer of Insmed. "Thank you to our colleagues around the world who show up every day with a desire to help patients, enrich our communities, and support one another. It is because of you that we have once again been recognized by Science as the top employer in the biopharma industry."
The complete feature and company rankings can be accessed here. To learn more about Insmed's culture and explore opportunities to join our team, please visit https://insmed.com/culture/careers/.
About Insmed
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in
Headquartered in
Contact:
Investors:
Bryan Dunn
Executive Director, Investor Relations
Insmed
(646) 812-4030
bryan.dunn@insmed.com
Media:
Mandy Fahey
Vice President, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-ranks-no-1-on-sciences-2024-top-biopharma-employers-list-302286466.html
SOURCE Insmed Incorporated
FAQ
What ranking did Insmed (INSM) achieve in Science's 2024 Top Employers Survey?
How many employees does Insmed (INSM) have globally in 2024?
What was the geographic distribution of respondents in Science's 2024 Top Employers Survey?
What key areas did Insmed (INSM) excel in according to the 2024 Science survey?
